Market Cap 3.93B
Revenue (ttm) 0.00
Net Income (ttm) -118.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.21
Volume 839,686
Avg Vol 515,566
Day's Range N/A - N/A
Shares Out 64.23M
Stochastic %K 44%
Beta 1.27
Analysts Strong Sell
Price Target $76.80

Company Profile

MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Industry: Biotechnology
Sector: Healthcare
Phone: 41 415108022
Address:
Dorfstrasse 29, Zug, Switzerland
MrCompassion
MrCompassion Sep. 10 at 10:23 PM
$IFRX All the best to $MLTX with HS p3 data expected soon, still trading at an mcap well above $3 billion, $MRK still potentially interested in acquiring the company in this price range. Exciting times, noting the past success of sonelokimab-HS, https://www.dermatologytimes.com/view/moonlake-immunotherapeutics-announces-24-week-data-of-sonelokimab-for-hs. All eyes on draining tunnel reduction, the greatest impact on quality of life for HS patients. Around the same time we’re also expecting InflaRx INF904-HS p2a data, looking to see if C5a-C5aR1 signaling control continues to show safe and significant reduction in draining tunnels as seen in the Vilo-HS p2 study.
0 · Reply
1986iamwallstreet
1986iamwallstreet Sep. 10 at 2:28 PM
$MLTX could have a massive move to the upside
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 9 at 12:19 PM
$MLTX Outstanding article that hits the mark on MLTX's current state. So if you want to refresh your MLTX insights or learn about MLTX from scratch, this is a must read. https://beyondspx.com/quote/MLTX/analysis/moonlake-immunotherapeutics-unpacking-the-sonelokimab-story-ahead-of-key-data-mltx
0 · Reply
informed_investor
informed_investor Sep. 8 at 7:45 PM
$MLTX Quizz: price upon successful data read?
1 · Reply
highnihilism
highnihilism Sep. 8 at 6:28 PM
$MLTX MoonLake secured up to $500M in non-dilutive financing (drawing $75M now) to support growth & its sonelokimab launch. Bulls call it smart capital structuring; bears note that when a biotech’s main news is financing, it’s usually because the science alone won’t carry the stock. #BTC Bitcoin’s on-chain metrics & institutional flows are propping up the $112,000 level, while Fed rate-cut speculation & “liquidity expansion” drive speculation about fresh all-time highs. #ETSY Etsy’s platform engagement & merchant growth are reinforcing the $72 level, while consumer-spending resilience (whimsy goth, fetish fashion, handmade crafts, domestic charm) drive speculation about yearly highs. #XHB Homebuilder demand trends & housing supply dynamics are reinforcing the $120 level, while Fed rate-cut speculation & “resilient housing momentum” spark fresh yearly highs.
0 · Reply
traderjoe90
traderjoe90 Sep. 5 at 3:54 PM
$MLTX playa layin wood in Nov 75 calls. $543,400
1 · Reply
Doozio
Doozio Sep. 5 at 3:35 PM
Wen $MLTX ? 🐒🍌🧠⏰♾️
0 · Reply
Irish_lass
Irish_lass Sep. 5 at 1:58 PM
0 · Reply
TheBiotechInvestor_
TheBiotechInvestor_ Sep. 4 at 7:44 PM
0 · Reply
TheBiotechInvestor_
TheBiotechInvestor_ Sep. 4 at 7:30 PM
$MLTX https://youtu.be/esj0FSOZpwk
1 · Reply
Latest News on MLTX
2 Logical Mid-Cap Biotech Buyout Targets

Aug 27, 2025, 12:50 PM EDT - 14 days ago

2 Logical Mid-Cap Biotech Buyout Targets

ABVX


MoonLake Immunotherapeutics: A Buy At Dips

Apr 8, 2025, 3:31 AM EDT - 5 months ago

MoonLake Immunotherapeutics: A Buy At Dips


MoonLake Immunotherapeutics Is Now Thoroughly De-Risked

Sep 27, 2023, 8:00 PM EDT - 2 years ago

MoonLake Immunotherapeutics Is Now Thoroughly De-Risked


Strong Mid-Cap Insider Buys: Q2 2023

Jul 24, 2023, 2:45 PM EDT - 2 years ago

Strong Mid-Cap Insider Buys: Q2 2023

ABCB ADC CLF CNX DISH EWBC GME


Exclusive: MoonLake Immunotherapeutics explores sale-sources

Jul 14, 2023, 3:38 PM EDT - 2 years ago

Exclusive: MoonLake Immunotherapeutics explores sale-sources


MoonLake: Further Gains Possible With End Of 2023 Data Releases

Jun 27, 2023, 5:50 PM EDT - 2 years ago

MoonLake: Further Gains Possible With End Of 2023 Data Releases


MrCompassion
MrCompassion Sep. 10 at 10:23 PM
$IFRX All the best to $MLTX with HS p3 data expected soon, still trading at an mcap well above $3 billion, $MRK still potentially interested in acquiring the company in this price range. Exciting times, noting the past success of sonelokimab-HS, https://www.dermatologytimes.com/view/moonlake-immunotherapeutics-announces-24-week-data-of-sonelokimab-for-hs. All eyes on draining tunnel reduction, the greatest impact on quality of life for HS patients. Around the same time we’re also expecting InflaRx INF904-HS p2a data, looking to see if C5a-C5aR1 signaling control continues to show safe and significant reduction in draining tunnels as seen in the Vilo-HS p2 study.
0 · Reply
1986iamwallstreet
1986iamwallstreet Sep. 10 at 2:28 PM
$MLTX could have a massive move to the upside
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 9 at 12:19 PM
$MLTX Outstanding article that hits the mark on MLTX's current state. So if you want to refresh your MLTX insights or learn about MLTX from scratch, this is a must read. https://beyondspx.com/quote/MLTX/analysis/moonlake-immunotherapeutics-unpacking-the-sonelokimab-story-ahead-of-key-data-mltx
0 · Reply
informed_investor
informed_investor Sep. 8 at 7:45 PM
$MLTX Quizz: price upon successful data read?
1 · Reply
highnihilism
highnihilism Sep. 8 at 6:28 PM
$MLTX MoonLake secured up to $500M in non-dilutive financing (drawing $75M now) to support growth & its sonelokimab launch. Bulls call it smart capital structuring; bears note that when a biotech’s main news is financing, it’s usually because the science alone won’t carry the stock. #BTC Bitcoin’s on-chain metrics & institutional flows are propping up the $112,000 level, while Fed rate-cut speculation & “liquidity expansion” drive speculation about fresh all-time highs. #ETSY Etsy’s platform engagement & merchant growth are reinforcing the $72 level, while consumer-spending resilience (whimsy goth, fetish fashion, handmade crafts, domestic charm) drive speculation about yearly highs. #XHB Homebuilder demand trends & housing supply dynamics are reinforcing the $120 level, while Fed rate-cut speculation & “resilient housing momentum” spark fresh yearly highs.
0 · Reply
traderjoe90
traderjoe90 Sep. 5 at 3:54 PM
$MLTX playa layin wood in Nov 75 calls. $543,400
1 · Reply
Doozio
Doozio Sep. 5 at 3:35 PM
Wen $MLTX ? 🐒🍌🧠⏰♾️
0 · Reply
Irish_lass
Irish_lass Sep. 5 at 1:58 PM
0 · Reply
TheBiotechInvestor_
TheBiotechInvestor_ Sep. 4 at 7:44 PM
0 · Reply
TheBiotechInvestor_
TheBiotechInvestor_ Sep. 4 at 7:30 PM
$MLTX https://youtu.be/esj0FSOZpwk
1 · Reply
Irish_lass
Irish_lass Sep. 3 at 6:52 PM
0 · Reply
MaverikIT
MaverikIT Sep. 3 at 2:04 PM
0 · Reply
Irish_lass
Irish_lass Sep. 3 at 1:47 PM
$MLTX Data news?
0 · Reply
Irish_lass
Irish_lass Sep. 2 at 3:33 PM
0 · Reply
StockConsultant
StockConsultant Sep. 2 at 1:19 PM
$MLTX MoonLake Immunotherapeutics stock, good day, watch for a narrow range breakout at https://stockconsultant.com/?MLTX
1 · Reply
judgeyoung2
judgeyoung2 Aug. 29 at 4:54 PM
$MLTX data should come any day now. i have shares and puts to hedge
0 · Reply
biolover
biolover Aug. 29 at 4:40 AM
$VKTX GLP1 drugs in JAMA dermatology for hidradenitis suppurativa.. please inform $MLTX ( and possibly $MRK) and $NVS that GLP1 coming to you. Like GLP1 coming for MASH and several big TAMs ( including unthought of massive indications such as chronic back pain) At least $PFE @AlbertBourla team appreciates scale of human health benefits , unlike $MRK that will spend billions on another IL17 nano body
1 · Reply
TraderNice
TraderNice Aug. 27 at 5:21 PM
$MLTX when is their FDA date of the top line information?
1 · Reply
dogDazeSummer
dogDazeSummer Aug. 25 at 1:22 PM
$IFRX Below is a July podcast I missed that underscores the reason some believe INF904 is multi billion maker. *But—-and *Before that can happen- —how do we get 1 immuno past the FDA finish line with current resources? This is the question. No scenario allows “go it alone” approach if we need 2-3x market capitalization in cash. Beyond Biotech asks —how do you capitalize on things like dementia and cancer knowing C5a (r) is implicated”? “We can’t right now -(resources)we’re focused on immuno derm” 25:46. (Applications beyond anti-inflammatories). But could we do this with $LLY who added so much value w weigh loss ——or a competitor like $MLTX ? I would have liked to see immediate partner day of European approval-same here w CSU/HS—-we need to “partner up” and split the multi $B pot. https://podcasts.apple.com/us/podcast/beyond-biotech-the-podcast-from-labiotech/id1629447269?i=1000717845685
1 · Reply
TheBiotechInvestor_
TheBiotechInvestor_ Aug. 22 at 9:52 PM
$MLTX My Top 5 Biotech Stocks Set to Explode Before 2026 | FDA Decisions & Data Catalysts Ahead https://youtu.be/AWl1dHkqXHs
0 · Reply
Irish_lass
Irish_lass Aug. 22 at 8:45 PM
0 · Reply
justiceforb_85
justiceforb_85 Aug. 18 at 1:02 AM
$MLTX wondering if the stock is already priced in for a successful P3 for sonelokimab?
2 · Reply